These effects, coupled with the observed synergistic efficacy of apatinib and PD-1 antibodies in inhibiting colorectal cancer growth, underscore the translational potential of targeting the VEGFR2–MYOF–PD-L1 axis. Here, KDR is linked to colorectal cancer.